Download Profile Form for

Profile Form for
2011 EU-FP7 HEALTH CALLS
Profile Form
Name
Hung-Cheng Lai
Gender
Male
Organization
Organization Name:
Department of Ob/Gyn, Tri-Service General Hospital
School of Medicine, National Defense Medical Center
URL:
http://www.tsgh.ndmctsgh.edu.tw/en/eindex.asp
http://www.ndmctsgh.edu.tw/default.aspx?webid=1&lid=EN
Address:
5F, No.325,Sec.2,Chenggong Rd.,Neihu District,Taipei City
114,Taiwan(R.O.C)
Telephone
+886 2 87923311 ext 10083
Email
[email protected]
Keywords specifying the
Epigenetics, DNA methylation, Cancer stem cells, cervical
cancer, ovarian cancer, biomarkers
expertise
Description of research activity
My research interest focuses on two themes:
“Epigenetics “ and “Cancer Stem Cells”. The long
term goals are to discover novel diagnostic markers
and therapeutic targets. In epigenetics, we are
using various genome-wide approaches to discover
novel DNA methylation in cervical and ovarian
cancer, and trying to translate these DNA
methylation markers to clinical diagnostics. By the
end of 2009, 10 genes have been patented for the
detection of various cancers detection. Assays of 7
genes have been standardized for clinical
diagnostics. Four genes are in a multi-center clinical
trial for cervical cancer detection now in Taiwan.
Novel genes with interest undergo functional
characterization from molecular biology to cell
biology and animal studies. In cancer stem cells, we
have successfully isolated ovarian/breast cancer
stem cells from cell lines and primary tumors. We
are exploring the epigenomics of ovarian cancer
stem cells including DNA methylation and
microRNA. By using high throughput drug
screening, we have identified some compounds
selectively targeting ovarian cancer stem cells,
which have been validated in vitro and in preclinical
animal models. The patent is pending. We will plan
clinical trials in the coming future.
S&T Publications/Patents
1. Lai HC* Lin YW ; Huang RL, Chung MT; Wang HC, Liao YP, Su
PH, Yu MH, Quantitative DNA methylation analysis detects
cervical intraepithelial neoplasm 3 and worse
Cancer 2010
Jun 8. (SCI) . (IF:5.418; Rank:20/165=12.12%)
2. Su HY, Lai HC Lin YW, Liu CY, Chou YC, Lin SP, Lin WC, Yu
MH, Epigenetic silencing of SFRP5 is related to malignant
phenotype and chemoresistance of ovarian cancer through
Wnt signaling pathway.Int. J. Cancer 2010 Aug 1;127(3):555-67.
(SCI) (IF:4.722;Rank:29/165=17.58%)
3. Liu CY, Chao TK, Su PH, Lee HY, Shih YL, Su HY, Chu TY, Yu
MH, Lin YW *, Lai HC* Characterization of LMX-1A as a
metastasis
suppressor
in
cervical
cancer.
Journal
of
Pathology 2009 Oct;219(2):222-31 (*Corresponding Author)
(SCI) (IF:6.466; Rank:2/71=2.82%)
4. Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH,
Chu TY, Lai HC*, Lin YW*. (2009)Promoter Methylation of
SFRPs Gene Family in Cervical Cancer. Gynecol Oncol. 2009
Feb;112(2):301-6. (*Corresponding Author) (SCI) (IF:3.733;
Rank:5/70=7.14%)
5. Chung MT, Lai HC, Sytwu HK, Yan MD, Shih YL, Chang CC,
Yu MH, Liu HS, Chu DW, Lin YW.(2009)SFRP1 and SFRP2
suppress the transformation and invasion abilities of cervical
cancer cells through Wnt signal pathway. Gynecol Oncol.
2009 Mar;112(3):646-53 (SCI) (IF:3.733; Rank:5/70=7.14%)
6. Su HY, Lai HC*, Lin YW, Chou YC, Liu CY, Yu MH*.( 2009) An
Epigenetic Marker Panel for Screening and Prognostic
Prediction of Ovarian Cancer.
15;124(2):387-393
Int. J. Cancer: 2009 Jan
(*Corresponding
Author)
(SCI)
(IF:4.722;Rank:29/165=17.58%)
7. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM,
Yan PS, Huang TH, Nephew KP.(2008) Identification and
characterization of ovarian cancer-initiating cells from primary
human tumors. Cancer Res. 2008 Jun 1;68(11):4311-20. (SCI)
(IF:7.543; Rank:13/165=7.88%)
8. Lai HC*, Lin YW, Huang T, Yan P,
Huang RL, Wang HC, Liu J,
Chan M, Chu TY, Sun CA, Chang CC, Yu MH.(2008)
Identification of Novel DNA methylation Markers in Cervical
Cancer.
Int J Cancer. 2008 Jul 1;123(1):161-7 (SCI)
(IF:4.722;Rank:29/165=17.58%)
9. Lai HC, Lin YW, Chang CC, Wang HC, Chu TW, Yu MH, Chu
TY* (2007). Hypermethylation of two consecutive tumor
suppressor genes, BLU and RASSF1A, located at 3p21.3 in
cervical neoplasias. Gynecol Oncol Mar;104(3):629-35. (SCI)
(IF:3.733; Rank:5/70=7.14%)
Patent:
I. Cancer Screening Method:
(country/Application No./Filing Date)
1.
Taiwan / 96102422 (approved in 2010) / Jan 23
2007
2.
3.
4.
China / 200810094659.2 / Apr 29 2008
United States / 11/764,051 / Jun 15 2007
Malaysia / UI20085354 / Dec 30 2008
II. Cancer Screening Method:
(country/Application No./Filing Date)
1.
2.
3.
4.
Taiwan / 098112589 / Apr 16 2009
China / 200910135501.X / Apr 17 2009
PCT / PCT/CN2009/000411 / Apr 17 2009
United States / 12/543,400 / Aug 18 2009
Research Topics of Interest
(Please see WP 2011) e.g.
HEALTH.2011.2.3.1-3
Health.2011.2.4.1-2
I agree with the publication of my contact data:
Yes
No
Please fill in this profile form and return it to Taiwan Health National Contact Point
Office before July 30th, 2010 at: [email protected]